We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byMegan Adams
Modified over 3 years ago
Cardiovascular effects of anti-hyperglycemic therapy Edoardo Mannucci Diabetes Agency Careggi teaching hospital, Firenze, Italy
MACE CV mort.
Effects of intensified glycemic control on CV mortality
MYOCARDIAL ISCHEMIA Adrenercic activation could have a negative impact on the prognosis of
Secondary prevention of macrovascular events in patients with type 2 diabetes: The PROACTIVE Study Dormandy JA et al., Lancet 2005; 366: 1279
Relative risk SU vs other therapies vs. Conventional vs. Insulin vs. Metformin Mortality0.961.031.53 MI0.830.911.24 Stroke1.191.402.12
Effect of SU on MACE Monami M, Ganovese S, Mannucci E – 2013 [in press]
Effect of SU on mortality Monami M, Ganovese S, Mannucci E – 2013 [in press]
An initiative of South Asian Federation of Endocrine Societies (SAFES)
PPAR activation Clinical evidence. Evolution of clinical evidence supporting PPAR activation and beyond Surrogate outcomes studies Large.
VBWG PROactive: Study design Dormandy JA et al. Lancet. 2005;366: Charbonnel B et al. Diabetes Care. 2004;27: Objective: Assess the effects.
Part 3. Diabetes Report Card: HbA 1c Levels in the United States Hoerger TJ, et al. Diabetes Care. 2008;31: Patients (%) HbA 1c (%) <
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.
Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.
Glycemic Control: When the Lower is Not the “Better”?
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
Vascular effects of PPAR activation: Inflammation.
Type 2 diabetes and high blood pressure How explosive is the cocktail?
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
Demystifying Cardiovascular Safety of Sulfonylurea.
1 Part 1 Importance of Identifying and Managing Postprandial Hyperglycemia An Educational Service from G LYCO M ARK G LYCO M ARK is a registered trademark.
The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.
Prevalence (%) estimates of diabetes (20-79 years) 2010.
VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.
FDA Endocrinologic and Metabolic Drugs Advisory Committee 1st June 2008 Rury Holman Clinical outcomes with anti-diabetic drugs: What we already know.
Trial profile Prakash Deedwania, et al. Lancet 2006; 368:
Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:
Ian Graham et al. European Heart Journal 2007;28:
P H Y S I C I A N S ’ A C A D E M Y F O R C A R D I O V A S C U L A R E D U C A T I O N Oral drugs for type 2 diabetes and all cause mortality in General.
Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
Treating Type 2 Diabetes in Obese Patients with Bariatric / Metabolic Surgery Highlights of Evidence from Recent Studies NAME DATE ©2012 Ethicon Endo-Surgery,
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Therapy of Type 2 Diabetes Mellitus: UPDATE Glycemic Goals in the Care of Patients with Type 2 Diabetes ADA and AACE Guidelines: Room For Improvement.
New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Analysis of the ADVANCE Trial Sapna N. Patel UCSF Pharm. D. Candidate 2008 Preceptor Dr. Craig S. Stern March 28, 2008.
Diabetes and the Kidney Richard Kingston Department of Renal Medicine Kent and Canterbury Hospital.
The “geriatric process” 1.Assesment a)Health (diagnoses, prognosis) b)Function (physical, mental) c)Resources (culture, education, social, economic) 2.Agree.
1 MT vs CT: 28 day survival Number at risk CT MT day % Surviving Monotherapy.
Current Management of Type 1 and Type 2 Diabetes Thomas Donner, M.D. Division of Endocrinology & Metabolism.
Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
Limitations and opportunities of insulin therapy
Is it useful to control blood pressure faster in hypertensive patients? Based on: Gradman AH et al. Hypertension. 2013;61:
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk.
Secondary Prevention & Cardiac Rehabilitation Malcolm Walker Consultant Cardiologist UCLH & the Heart Hospital, London.
Modern Management of Cholesterol in the High-Risk Patient.
Diabetes Mellitus 101 for Medical Professionals
Individualizing Targets and Tactics for High- Risk Patients With Type 2 Diabetes Practical lessons from ACCORD and other cardiovascular trials Featured.
A Review of – Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Ted Williams Pharm D Candidate Monday Lab.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Short- and Long-Term Mortality After Myocardial Infarction in Patients With and Without Diabetes Featured Article: Sjoerd T. Nauta, M.S.C., Jaap W. Deckers,
Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.
PowerHour Information 03/09/2011. Background Description Vision Mission Measurements Participation Requirements.
Trial profile Fox K et al. Lancet 2008;372:
© 2017 SlidePlayer.com Inc. All rights reserved.